Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Cancer Discovery

• Publication date

  2012-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/2159-8290.CD-11-0320PMID 22628408
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Checkpoint control and cancer

  2012cited by this paper
• WEE1 Kinase Targeting Combined with DNA-Damaging Cancer Therapy Catalyzes Mitotic Catastrophe

  2011cited by this paper
• WEE1 inhibition sensitizes osteosarcoma to radiotherapy

  2011cited by this paper
• Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation

  2011cited by this paper
• Functional viability profiles of breast cancer.

  2011cited by this paper
• Targeting Radiation-Induced G2 Checkpoint Activation with the Wee-1 Inhibitor MK-1775 in Glioblastoma Cell Lines

  2011cited by this paper
• MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer Xenografts

  2011cited by this paper
• Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication

  2011cited by this paper
• Wee1 controls genomic stability during replication by regulating the Mus81-Eme1 endonuclease

  2011cited by this paper
• MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells

  2011cited by this paper
• EZH2-Dependent Suppression of a Cellular Senescence Phenotype in Melanoma Cells by Inhibition of p21/CDKN1A Expression

  2011cited by this paper
• MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil

  2010cited by this paper
• Mechanisms of centrosome separation and bipolar spindle assembly.

  2010cited by this paper
• Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome

  2010cited by this paper
• New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network

  2010cited by this paper
• Regulators of cyclin-dependent kinases are crucial for maintaining genome integrity in S phase

  2010cited by this paper
• Comparison of mitotic cell death by chromosome fragmentation to premature chromosome condensation

  2010cited by this paper
• In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma.

  2010cited by this paper
• B-MYB is required for recovery from the DNA damage-induced G2 checkpoint in p53 mutant cells.

  2009cited by this paper
• Integrative Analysis of Cyclin Protein Levels Identifies Cyclin B1 as a Classifier and Predictor of Outcomes in Breast Cancer

  2009cited by this paper
• Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents

  2009cited by this paper
• The decision to enter mitosis: feedback and redundancy in the mitotic entry network

  2009cited by this paper
• High cyclin B1 expression is associated with poor survival in breast cancer

  2009cited by this paper
• AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies

  2008influential reference
• Down-regulation of Enhancer of Zeste-2 decreases growth of estrogen receptor negative invasive breast carcinoma and requires BRCA1

  2008cited by this paper
• LINC, a Human Complex That is Related to pRB-Containing Complexes in Invertebrates Regulates the Expression of G2/M Genes

  2007cited by this paper
• TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer

  2007cited by this paper
• Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer.

  2006cited by this paper
• CHK1 phosphorylates CDC25B during the cell cycle in the absence of DNA damage

  2006cited by this paper
• Genomic and transcriptional aberrations linked to breast cancer pathophysiologies.

  2006cited by this paper
• Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies

  2006cited by this paper
• An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival.

  2005cited by this paper
• Mammalian cell cycle checkpoints: signalling pathways and their organization in space and time.

  2004cited by this paper
• Knockdown of Chk1, Wee1 and Myt1 by RNA Interference Abrogates G2 Checkpoint and Induces Apoptosis

  2004cited by this paper
• Centrosome-associated Chk1 prevents premature activation of cyclin-B–Cdk1 kinase

  2004cited by this paper
• Checking on DNA damage in S phase

  2004cited by this paper
• Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint.

  2004cited by this paper
• EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells

  2003cited by this paper
• ATR-Mediated Checkpoint Pathways Regulate Phosphorylation and Activation of Human Chk1

  2001cited by this paper
• Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator.

  2001cited by this paper
• Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

  2001cited by this paper
• p21 Inhibits Thr161 Phosphorylation of Cdc2 to Enforce the G2 DNA Damage Checkpoint*

  2000cited by this paper
• Requirement for p53 and p21 to sustain G2 arrest after DNA damage.

  1998cited by this paper
• Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25.

  1997cited by this paper
• Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation

  1997cited by this paper
• p21 is a universal inhibitor of cyclin kinases

  1993cited by this paper
• For April.

  1903cited by this paper

• Transcriptional activation of PPP1R14C by KLF7 unleashes CDK1 activity to promote lung squamous cell carcinoma.

  2026cites this paper
• Defective DNA Damage Response is a Targetable Therapeutic Vulnerability in ESR1 Mutant Breast Cancer.

  2026cites this paper
• Immune Evasion in Pancreatic Ductal Adenocarcinoma: Mechanistic Insights and Emerging Strategies to Reinvigorate Anti-Cancer Immunity

  2026cites this paper
• Targeting WEE1 in ARID1A/TP53 Concurrent Mutant Colorectal Cancer by Exploiting R‐Loop Accumulation and DNA Repair Deficiencies

  2025cites this paper
• Translational Aspects of DNA Damage Repair in Optimizing Cancer Chemotherapy

  2025cites this paper
• A nuclease-driven mechanism of post-replicative ssDNA gap suppression

  2025cites this paper
• Preparation for mitosis requires gradual CDK1 activation

  2025cites this paper
• Emerging opportunities to treat drug-resistant breast cancer: Discovery of novel small-molecule inhibitors against different targets

  2025cites this paper
• Anti-cancer drug sensitivity testing and preclinical evaluation of the anti-cancer potential of WEE1 inhibitor in triple-negative breast cancer patient-derived organoids and xenograft models

  2025cites this paper
• Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors

  2025cites this paper
• WEE1 inhibition delays resistance to CDK4/6 inhibitor and antiestrogen treatment in ER+ MCF7 cells

  2025cites this paper
• Targeting DNA Damage Repair Pathways Beyond PARP Inhibition

  2025cites this paper
• A quantitative model‐based approach for adavosertib dose selection in patients with uterine serous carcinoma

  2025cites this paper
• Aqueous synthesis of Fe-Au@CD nanoconjugates: Characterization, assessment of their optical behaviour and cytotoxicity potential

  2025cites this paper
• A prognostic gene signature derived from aging-related genes predicts survival, immune landscape and therapy response in glioma

  2025cites this paper
• Exploiting dysregulated iron homeostasis to eradicate persistent high-grade serous ovarian cancer

  2025cites this paper
• Targeted delivery of the PKMYT1 inhibitor RP-6306 mediates PANoptosis in pancreatic cancer via mitotic catastrophe

  2025cites this paper
• DNA damage response signaling in oocytes from an oncofertility perspective.

  2025cites this paper
• Checkpoint kinase Wee1 activation drives inflammation and hypertrophy through the protein kinase B/phosphoinositide 3-kinases-nuclear factor κB pathway in cardiomyocytes.

  2025cites this paper
• High WEE1 expression is independently linked to poor survival in multiple myeloma

  2025cites this paper
• Controversies in the management of mucinous ovarian tumors.

  2025cites this paper
• WEE1 inhibitors trigger GCN2-mediated activation of the integrated stress response

  2025cites this paper
• Regulation of nucleotide excision repair by wild-type HRAS signaling in head and neck cancer

  2025cites this paper
• Targeting WEE1 Kinase for Breast Cancer Therapeutics: An Update

  2025cites this paper
• Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial

  2024cites this paper
• WEE1 inhibition delays resistance to CDK4/6 inhibitor and antiestrogen treatment in estrogen receptor-positive breast cancer

  2024cites this paper
• Therapeutic potential of targeting the FLNA‐regulated Wee1 kinase in adrenocortical carcinomas

  2024cites this paper
• DNA damage response in breast cancer and its significant role in guiding novel precise therapies

  2024cites this paper
• High WEE1 expression is independently linked to poor survival in multiple myeloma

  2024cites this paper
• AutoDesigner - Core Design, a De Novo Design Algorithm for Chemical Scaffolds: Application to the Design and Synthesis of Novel Selective Wee1 Inhibitors

  2024cites this paper
• Population Pharmacokinetic Modeling of Adavosertib (AZD1775) in Patients with Solid Tumors

  2024cites this paper
• Wee1 inhibition decouples Cdk1 and Plk1 activities: a role for gradual Cdk1 activation throughout G2 phase

  2024cites this paper
• Exploiting WEE1 kinase activity as FUS::DDIT3-dependent therapeutic vulnerability in myxoid liposarcoma

  2024cites this paper
• NAMPT-targeting PROTAC and nicotinic acid co-administration elicit safe and robust anti-tumor efficacy in NAPRT-deficient pan-cancers.

  2024cites this paper
• New insight into targeting the DNA damage response in the treatment of glioblastoma.

  2024cites this paper
• Genome-wide CRISPR screens identify PKMYT1 as a therapeutic target in pancreatic ductal adenocarcinoma

  2024cites this paper
• DNA repair-dependent immunogenic liabilities in colorectal cancer: opportunities from errors

  2024cites this paper
• Adavosertib-encapsulated metal-organic frameworks for p53-mutated gallbladder cancer treatment via synthetic lethality.

  2024cites this paper
• Rac1 promotes kidney collecting duct repair by mechanically coupling cell morphology to mitotic entry

  2024cites this paper
• Molecular biomarkers of progression in non-muscle-invasive bladder cancer — beyond conventional risk stratification

  2024cites this paper
• WEE1 Inhibitor Adavosertib Exerts Antitumor Effects on Colorectal Cancer, Especially in Cases with p53 Mutations

  2024cites this paper
• Genome-wide Mapping of Topoisomerase Binding Sites Suggests Topoisomerase 3α (TOP3A) as a Reader of Transcription-Replication Conflicts (TRC)

  2024cites this paper
• Potential promising of synthetic lethality in cancer research and treatment

  2024cites this paper
• Therapeutic Targeting of DNA Repair Pathways in Pediatric Extracranial Solid Tumors: Current State and Implications for Immunotherapy

  2024cites this paper
• In silico study of novel coumarin derivatives as potential agents in the pancreatic cancer treatment.

  2024cites this paper
• Open-Label, Multicenter, Phase I Study to Assess Safety and Tolerability of Adavosertib Plus Durvalumab in Patients with Advanced Solid Tumors

  2024cites this paper
• Strategies for the Management of Patients with Pancreatic Cancer with PARP Inhibitors.

  2023cites this paper
• Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors

  2023cites this paper
• Proteolysis Targeting Chimera (PROTAC) as a promising novel therapeutic modality for the treatment of triple‐negative breast cancer (TNBC)

  2023influential citation
• DNA Damage Response Inhibition-Based Combination Therapies

  2023cites this paper
• FBXW7-loss Sensitizes Cells to ATR Inhibition Through Induced Mitotic Catastrophe

  2023cites this paper
• Combination Therapy as a Promising Way to Fight Oral Cancer

  2023cites this paper
• Systemic Therapy for Hereditary Breast Cancers.

  2023cites this paper
• A phase I study of the Wee1 kinase inhibitor adavosertib (AZD1775) in combination with chemoradiation in cervical, upper vaginal, and uterine cancers

  2023cites this paper
• Individualisierte Präzisionsmedizin

  2023cites this paper
• Discovery of pyrido[4,3-d]pyrimidinone derivatives as novel Wee1 inhibitors.

  2023cites this paper
• FBH1 deficiency sensitizes cells to WEE1 inhibition by promoting mitotic catastrophe

  2023cites this paper
• Review: Mechanisms and perspective treatment of radioresistance in non-small cell lung cancer

  2023cites this paper
• Harnessing DNA replication stress to target RBM10 deficiency in lung adenocarcinoma

  2023cites this paper
• The Landscape and Therapeutic Targeting of BRCA1, BRCA2 and Other DNA Damage Response Genes in Pancreatic Cancer

  2023cites this paper
• PARP inhibitors: enhancing efficacy through rational combinations

  2023cites this paper
• The evolving role of DNA damage response in overcoming therapeutic resistance in ovarian cancer

  2023cites this paper
• Advances in DNA damage response inhibitors in colorectal cancer therapy

  2023cites this paper
• Adavosertib and Beyond: Biomarkers, Drug Combination and Toxicity of WEE1 Inhibitors.

  2023cites this paper
• Combination DNA Damage Response (DDR) Inhibitors to Overcome Drug Resistance in Ovarian Cancer.

  2023cites this paper
• Discovery of Tetrahydropyrazolopyrazine Derivatives as Potent and Selective MYT1 Inhibitors for the Treatment of Cancer.

  2023cites this paper
• 2pClPr: A Two-Phase Clump Profiler for Segmentation of Cancer Cells in Fluorescence Microscopic Images

  2023cites this paper
• FBXL12 degrades FANCD2 to regulate replication recovery and promote cancer cell survival under conditions of replication stress.

  2023cites this paper
• Broadening the scope of WEE1 inhibitors: identifying novel drug candidates via computational approaches and drug repurposing

  2023cites this paper
• Wee1 inhibition by MK1775 potentiates gemcitabine through accumulated replication stress leading to apoptosis in biliary tract cancer.

  2023cites this paper
• Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy

  2023cites this paper
• Adavosertib (AZD1775) does not prolong the QTc interval in patients with advanced solid tumors: a phase I open-label study

  2023cites this paper
• Myt1 overexpression mediates resistance to cell cycle and DNA damage checkpoint kinase inhibitors

  2023cites this paper
• Targeting the DNA Damage Response and DNA Repair Pathways to Enhance Radiosensitivity in Colorectal Cancer

  2022cites this paper
• PD0166285 sensitizes esophageal squamous cell carcinoma to radiotherapy by dual inhibition of WEE1 and PKMYT1

  2022cites this paper
• Modeling breast cancer proliferation, drug synergies, and alternating therapies

  2022cites this paper
• Targeting replication stress in cancer therapy

  2022cites this paper
• A key role of the WEE1-CDK1 axis in mediating TKI-therapy resistance in FLT3-ITD positive acute myeloid leukemia patients

  2022cites this paper
• Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance

  2022cites this paper
• Targeting the DNA damage response beyond poly(ADP-ribose) polymerase inhibitors: novel agents and rational combinations

  2022cites this paper
• Cell cycle involvement in cancer therapy; WEE1 kinase, a potential target as therapeutic strategy.

  2022cites this paper
• Therapeutic Targeting of DNA Damage Response in Cancer

  2022cites this paper
• Targeting the DNA Damage Response for Cancer Therapy by Inhibiting the Kinase Wee1

  2022cites this paper
• Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer

  2022cites this paper
• HJURP Promotes Malignant Progression and Mediates Sensitivity to Cisplatin and WEE1-inhibitor in Serous Ovarian Cancer

  2022influential citation
• The expanding role of WEE1.

  2022cites this paper
• Novel Therapeutic Targets and Immune Dysfunction in Malignant Pleural Mesothelioma

  2022cites this paper
• Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification

  2022cites this paper
• Therapeutic Targeting of DNA Damage Repair in the Era of Precision Oncology and Immune Checkpoint Inhibitors

  2022cites this paper
• Molecular selection of therapy in metastatic colorectal cancer: the FOCUS4 molecularly stratified RCT

  2022cites this paper
• Rational combinations of targeted cancer therapies: background, advances and challenges

  2022cites this paper
• High cyclin E1 protein, but not gene amplification, is prognostic for basal‐like breast cancer

  2022cites this paper
• Synthetic Lethality in Ovarian Cancer

  2021cites this paper
• Inhibition of WEE1 Is Effective in TP53- and RAS-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring

  2021cites this paper
• Discovery of ZN-c3, a Highly Potent and Selective Wee1 Inhibitor Undergoing Evaluation in Clinical Trials for the Treatment of Cancer.

  2021cites this paper
• Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells

  2021cites this paper
• WEE1 Inhibitor: Clinical Development

  2021cites this paper
• Targeting Wee1 kinase as a therapeutic approach in Hematological Malignancies.

  2021cites this paper
• A novel role for RNF126 in the promotion of G2 arrest via interaction with 14-3-3σ.

  2021cites this paper
• Recent Advances in Therapeutic Application of DNA Damage Response Inhibitors against Cancer.

  2021cites this paper